Gassner et al. developed an SPR-based test to evaluate the binding ability of a bispecific-bivalent anti-Ang-2/anti-VEGF antibody that interacts with either vascular endothelial growth factor A (VEGF-A) or angiopoietin-2 (Ang-2), resulting in tumor growth suppression owing to diminished angiogenesis [149]. The gene discussed is VEGFA; the disease is neoplasm.